This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Kite Pharma's Lead Program With The National Cancer Institute (NCI) Demonstrates Positive Results In Patients With Aggressive Non-Hodgkin's Lymphoma

LOS ANGELES, Dec. 7, 2013 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite's most advanced product candidate can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma.  In an oral presentation at the 55th ASH Annual Meeting, James N. Kochenderfer, MD, from the NCI reported that an infusion of patients' own genetically modified T lymphocytes resulted in six complete remissions (CR) and six partial remissions (PR) among 13 patients with advanced B-cell malignancies who were eligible for response assessment.

(Logo:  http://photos.prnewswire.com/prnh/20130513/MM13332LOGO)

Kite Pharma and the Surgery Branch of the NCI, led by Steven A. Rosenberg, MD, PhD, are collaborating under a Cooperative Research and Development Agreement (CRADA) for the development and commercialization of novel eACT products for the treatment of multiple cancer indications.  This technology utilizes patients' peripheral blood T lymphocytes genetically engineered with either chimeric antigen receptors (CAR) or T cell receptors (TCR) that recognize tumor-specific molecules, traffic directly to the tumor, become activated upon engagement with the tumor antigen, and selectively eradicate tumors.  The reported Phase 1/2a clinical trial is being conducted at the NCI with Dr. Rosenberg serving as principal investigator.

In the clinical trial, patients' T cells were modified to express a CAR targeting the B cell antigen CD19.  Among the nine patients with either chemotherapy-refractory primary mediastinal B cell lymphoma (PMBCL) or diffuse large B cell lymphoma (DLBCL), seven patients were evaluable for response.  Of these seven patients, six showed a response (three CR's and three PR's).  This is the first report of successful treatment of these patients with CD19 CAR T cells.  The majority of clinical responses were durable (up to 22 months ongoing).  Acute toxicities, including fever, low blood pressure, focal neurological deficits, and delirium occurred in some patients after cell infusion, but resolved in less than three weeks.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs